Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK7 | Q13164 | 8/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299630 | 0.85 | POLB (0.50) | POLBKMT2AMAPK7MAPK14ALDH1A1 | |
| SCHEMBL298824 | 0.80 | BAZ2B (0.55) | POLBKMT2AMAPK7MAPK14ALDH1A1 | |
| SCHEMBL10042102 | 0.76 | MAPK14 (0.52) | POLBKMT2AMAPK7MAPK14HTT | |
| SCHEMBL298212 | 0.72 | POLB (0.51) | POLBKMT2AMAPK7MAPK14ALDH1A1 | |
| SCHEMBL1507329 | 0.72 | MAPK7 (0.48) | POLBKMT2AMAPK7MAPK14GAA | |
| SCHEMBL289690 | 0.71 | CES2 (0.44) | KMT2AALDH1A1GAA | |
| SCHEMBL10029664 | 0.71 | CES2 (0.48) | KMT2AGAA | |
| SCHEMBL30395996 | 0.71 | SMYD3 (0.47) | KMT2AALDH1A1GAANPC1HTT | |
| SCHEMBL1507316 | 0.70 | L3MBTL1 (0.48) | MAPK7MAPK14ALDH1A1LMNAHTT | |
| SCHEMBL300049 | 0.70 | POLB (0.68) | POLBMAPK7MAPK14ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513289-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2012-02-16 | — | — | US | disclosed |
| WO-2010129208-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040999-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | POLB 2065/4885KMT2A 4754/4885MAPK7 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.